Skip to main content

Table 2 Baseline characteristics of breast cancer patients with liver metastases in the FUSCC dataset

From: Risk and prognostic factors of breast cancer with liver metastases

Variable

Patients, No. %

Patients (n = 1728)

Age at diagnosis, y

 21–40

288 (16.7%)

 41–60

1143 (66.1%)

  > 60

297 (17.2%)

Histology

 Infiltrating duct carcinoma

1396 (80.8%)

 Lobular carcinoma

31 (1.8%)

 Other

301 (17.4%)

De novo metastatic diseases

 No

1526 (88.3%)

 Yes

202 (11.7%)

Surgery of primary site

 No

219 (12.7%)

 Yes

1509 (87.3%)

Prior Chemotherapy

 No

226 (13.1%)

 Yes

1502 (86.9%)

Prior Radiotherapy

 No

848 (49.1%)

 Yes

785 (45.4%)

 Unknown

95 (5.5%)

Recurrent sequence

 First liver metastases

1087 (62.9%)

 Subsequent liver metastases

641 (37.1%)

Extrahepatic metastatic sites to lung, brain, bone and lymph nodes, No

 0

561 (32.5%)

 1

534 (30.9%)

 2

382 (22.1%)

 3

223 (12.9%)

 All 4

28 (1.6%)

Subtype

 HR+/HER2−

767 (44.3%)

 HR+/HER2+

305 (17.7%)

 HR−/HER2+

321 (18.6%)

 Triple-negative

270 (15.6%)

 Unknown

65 (3.8%)

  1. Notes: + denotes positive; − denotes negative; *denotes a statistically significant P-value; HER2, human epidermal growth factor receptor 2; HR, hormone receptor